8-K: ZyVersa Therapeutics Secures Up to $10 Million Equity Funding to Advance Kidney Disease Drug Development

ZyVersa Therapeutics, Inc. has entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC for up to $10 million in common stock sales to fund the clinical development of its Cholesterol Efflux MediatorTM VAR 200 for kidney diseases.

Summary

• ZyVersa Therapeutics, Inc. (the "Company") entered into an Equity Purchase Agreement (the "Purchase Agreement") with Williamsburg Venture Holdings, LLC (the "Purchaser") on June 24, 2025.
• Under the Purchase Agreement, the Company has the right, but not the obligation, to sell up to an aggregate of $10 million of its common stock to the Purchaser over a 24-month period, ending June 24, 2027.
• The purchase price for the shares will be 94% of the lowest Volume-Weighted Average Price (VWAP) of the common stock during the three business days subsequent to the clearing date of each share issuance.
• The Company will issue a commitment fee to the Purchaser equal to approximately 2.5% of the common stock sold, on a pro rata basis with each issuance.
• Sales under the agreement are capped at 19.99% of the Company's total outstanding common stock immediately prior to the agreement's execution, unless stockholder approval is obtained.
• The Company must file a registration statement with the SEC within 120 days of signing the Purchase Agreement (by October 21, 2025) to cover the resale of these shares.
• The Company intends to use the net proceeds from this financing to progress the clinical development of its Cholesterol Efflux MediatorTM VAR 200, a drug candidate for chronic kidney diseases.
• The global drug market for kidney diseases was $18 billion in 2024 and is projected to reach $30 billion by 2034, according to Precedence Research.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company successfully secured a flexible funding mechanism for its clinical development, which is crucial for a biopharmaceutical company. While there's inherent dilution risk with equity sales at a discount, the company retains control over the timing and amount, and the funds are earmarked for key strategic initiatives in a growing market. The forward-looking statements are optimistic about the drug's potential and market opportunity.

Positives

• Provides a flexible source of funding, allowing the Company to control the timing and amount of equity sales.
• Aims to minimize dilution while creating and sustaining shareholder value.
• Supports the progression of clinical development for Cholesterol Efflux MediatorTM VAR 200, addressing unmet medical needs in renal and inflammatory diseases.
• The agreement does not involve warrants, derivatives, or other complex share classes, simplifying the capital structure.

Negatives

• Sales of common stock to the Purchaser will occur at a discount (94%) to the market price, potentially leading to dilution for existing shareholders.
• The Company may need to obtain stockholder approval to issue shares exceeding 19.99% of its outstanding common stock, which could limit funding flexibility if not secured.

Risks

• The Company's ability to sell shares under the agreement is subject to market conditions and the trading price of its common stock.
• The availability of other sources of financing may influence the Company's decision to utilize this agreement.
• The SEC or its staff may seek to characterize the offering in a way that limits the number of Registrable Securities, potentially requiring additional registration statements.
• The effectiveness of the registration statement covering the resale of shares could be suspended or withdrawn by the SEC, impacting the Purchaser's ability to sell shares.
• Trading of the Common Stock could be suspended or delisted from Nasdaq, which would impact the Purchaser's obligation to buy shares and the Company's ability to raise funds.
• A minimum VWAP of $0.01 per share is required for a Put Notice to be valid, posing a risk if the stock price falls below this threshold.
• Failure to obtain stockholder approval for issuances exceeding the 19.99% cap could limit the total capital raised through this agreement.

Future Outlook

ZyVersa Therapeutics plans to strategically utilize the $10 million equity facility to advance the clinical development of its Cholesterol Efflux MediatorTM VAR 200, a key therapeutic candidate for chronic kidney diseases. The Company will consider market conditions, the trading price of its common stock, and the availability of other financing sources when determining the timing and amount of sales under the agreement, aiming to minimize shareholder dilution.

Management Comments

• "We anticipate that this partnership will provide a flexible source of funding, enabling the company to progress clinical development of Cholesterol Efflux MediatorTM VAR 200 to treat chronic kidney diseases." (Stephen Glover, Chief Executive Officer)
• "We aim to use the SPA in a manner that will minimize dilution while creating and sustaining shareholder value." (Stephen Glover, Chief Executive Officer)

Industry Context

The announcement positions ZyVersa Therapeutics within the growing global market for kidney disease drugs, which was valued at $18 billion in 2024 and is projected to reach $30 billion by 2034. This funding is intended to support the clinical development of VAR 200, a Cholesterol Efflux Mediator, and IC 100, an Inflammasome ASC Inhibitor, targeting significant unmet medical needs in renal and inflammatory diseases. The company's focus on first-in-class drugs aligns with the industry's pursuit of novel therapeutic solutions for complex conditions.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results to assess the financial terms or clinical progress against global benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the issuance of new common stock at a discount to market price, but benefit from the secured funding for clinical development which could enhance long-term value.
• Employees: Continued employment and potential for growth as clinical development progresses.
• Customers (future patients): Potential for new therapeutic options for renal and inflammatory diseases if VAR 200 and IC 100 development is successful.

Next Steps

• The Company will file a registration statement with the SEC within 120 days of June 24, 2025 (by October 21, 2025) to cover the resale of the ELOC Shares and Commitment Fee shares.
• The Company plans to progress the clinical development of Cholesterol Efflux MediatorTM VAR 200 for chronic kidney diseases.
• The Company will consider market conditions, the trading price of its common stock, and the availability of other financing sources when determining whether to make sales under the Purchase Agreement.

Key Dates

Keywords

ZyVersa Therapeutics, ZVSA, Equity Purchase Agreement, Williamsburg Venture Holdings, VAR 200, Kidney Diseases, Clinical Development, Biopharmaceutical, SEC Filing, 8-K, Equity Financing, Dilution, Common Stock, Nasdaq, Cholesterol Efflux Mediator, Inflammasome ASC Inhibitor, IC 100